Ophthalmology Times

12/28/2025

The year in optometry: 10 stories that defined eye care in 2025—The past year marked a pivotal period for optometry, with 2025 delivering meaningful clinical, regulatory, and legislative developments that reshaped eyecare practice.

An overview of the top 10 stories from Optometry Times in 2025.

12/27/2025

Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors on slit-lamp photographs. Another advance is more individualized cataract surgery thus enhancing precision and visual outcomes.

AI currently is at the forefront of ophthalmologists’ minds. When asked about technologic advances in 2025, a recent survey found that ophthalmologists identified AI as by far the “most transformative trend in ophthalmology.”

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

12/26/2025

Extended durability, higher molar dose, fewer injections. From our panel discussion, a trio of retina experts explore how aflibercept 8 mg is reshaping treatment strategy for retinal disease. .

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

12/26/2025

Topical liposomal ozonated oil may play an antiseptic role in the management of neurotrophic keratopathy (NK), potentially serving as an alternative to antibiotic therapy.

In a recent study from Spain, Giralt et al reported 3 cases of neurotrophic corneal ulcer that were successfully treated with topical liposomal ozonated oil eye drops (Ozonest; Esteve Pharmaceuticals SA). The authors evaluated the potential utility of these eye drops in managing neurotrophic corneal ulcers by preventing corneal infection and promoting epithelialization

Alternative management may avoid current concerns found with antibiotics.

12/24/2025

Wishing you a season filled with clear moments and bright perspectives. 🎄👁️
Thank you to the ophthalmologists whose expertise helps patients see what’s possible, today and all year long.

12/24/2025

Demodex blepharitis is more common than previously thought, and proper diagnosis and management are important for effective patient care.

Anne M. Zaki, MD, a cornea specialist in private practice at Desert Eye Specialists in Peoria, Arizona, moderated a recent Ophthalmology Times Case-Based Round-table on diagnosing and effectively treating Demodex blepharitis. Approximately 58% of patients presenting for an ocular examination have Demodex blepharitis, Zaki noted.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

12/23/2025

Siegfried G. Priglinger from the University Eye Hospital of Ludwig Maximilian University (LMU) Munich in Germany discusses the evolving realities in gene therapy for an inherited retinal disease

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

12/22/2025

How has aflibercept 8 mg changed your approach to anti-VEGF treatment?

Here are 8 key insights from our panel discussion, including early adoption and durable drying to improved practice flow and patient satisfaction.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

12/22/2025

Malar edema, the collection of fluid below the infraorbital rim and over the malar eminence, presents a unique challenge to providers in aesthetics and ophthalmology.

Despite their seemingly benign nature, the presence of malar edema or malar mounds (chronic soft tissue bulging) can significantly impact a patient’s appearance, confidence, and quality of life.

Insights for diagnosing and managing these visible changes across specialties.

12/21/2025

A timely and accurate diagnosis of retinal disease gives patients the best chance of achieving an optimal visual outcome. This is particularly true now, with the availability of drug treatments for geographic atrophy (GA) and inherited retinal diseases (IRDs) caused by biallelic mutations in the RPE65 gene.

As more developments emerge, it is important that eye care providers recognize the phenotypical similarities between macular atrophy associated with age-related macular degeneration (AMD) and IRD-associated atrophy.

This approach helps distinguish diseases associated with macular atrophy.

12/20/2025

As many as 40% of individuals with Graves disease will develop TED. The condition can also arise when thyroid hormone levels are normal (euthyroid) or even low (hypothyroid). TED may occur in patients already diagnosed with thyroid disease, or it can be the initial indication of Graves disease. Because TED is a distinct disorder, managing hyperthyroidism alone may not fully improve the eye-related symptoms or signs.

TED remains frequently misdiagnosed or misunderstood, and Lisa M. Nijm, MD, JD, is dedicated to improving clinical awareness and understanding.

“TED is a serious progressive and potentially vision-threatening, rare autoimmune disorder,” Nijm noted. “TED is often confused with hyperthyroidism and Graves disease, and many people incorrectly assume that TED occurs only in the presence of Graves disease.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

12/20/2025

Couldn’t make it to American Academy of Ophthalmology (AAO) 2025 or a Subspecialty Day session? Log into (or register for) AAO 2025 Virtual and catch up with some of the most high-demand sessions you missed: https://hubs.li/Q03YKgPh0